Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
和铂医药(上海)有限公司 Harbour BioMed
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
2024-09-14 16:06
Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
2024-09-13 09:27
Harbour BioMed Announces 2024 Interim Results
2024-08-28 17:44
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
2024-07-26 10:16
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
2024-07-19 07:15
Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy
2024-07-15 10:12
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
2024-06-27 07:08
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
2024-05-23 07:23
Harbour BioMed Reports Full Year 2023 Financial Results
2024-03-28 22:10
Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development
2024-02-27 09:23
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.
2024-01-24 12:40
Harbour BioMed Announces Positive Profit Alert
2024-01-19 12:52
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
2023-12-15 07:30
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery
2023-12-11 09:00
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
2023-12-04 13:19
Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates
2023-11-13 16:04
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
2023-10-13 23:26
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
2023-09-14 16:00
Harbour BioMed Announces 2023 Interim Results
2023-08-28 17:08
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
2023-08-28 16:30
1
2
3
4
5
7